Advertisement ViiV Healthcare secures Canadian approval for Triumeq to treat HIV-1 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

ViiV Healthcare secures Canadian approval for Triumeq to treat HIV-1

ViiV Healthcare, a joint venture of GlaxoSmithKline (GSK), Pfizer and Shionogi, has secured approval in Canada, for its Triumeq (dolutegravir 50mg, abacavir 600mg, and lamivudine 300mg) to treat patients with Human Immunodeficiency Virus (HIV-1) infection.

Triumeq is a once-daily single-pill regimen, which combines the integrase strand transfer inhibitor (INSTI) dolutegravir with the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine.

ViiV Healthcare Canada general manager Gregory Reinaud said, "Until we have a cure for HIV, we need new or different HIV medicines for patients. Everyone at ViiV is very proud that we can now offer Canadian physicians and patients living with HIV the first single-pill regimen containing dolutegravir."

In September, the company secured marketing authorization from the European Commission (EC) for Triumeq to treat HIV in adults and adolescents aged 12 years and older and weighing around 40kg.

The US Food and Drug Administration (FDA) has approved Triumeq in August 2014.

Dolutegravir received approval in the US in August 2013, while in Europe in January under the brand name Tivicay.

HIV infects specific cells of the immune system, known as CD4 cells or T-cells, and it leads to Acquired Immunodeficiency Syndrome (AIDS) which is the final stage of HIV infection.